布地奈德雾化吸入治疗尘肺病合并感染的临床观察及护理体会
Treatment of infection of pneumoconiosis patients with inhalation of budesonide aerosol
-
摘要:目的 观察布地奈德雾化吸入治疗对尘肺病合并感染患者的临床效果。方法 选取2015年1月-2016年1月期间入院治疗的尘肺病合并感染患者60例, 将其随机分为对照组(n=30)和观察组(n=30)。对照组患者采用常规治疗, 如吸氧、解痉、平喘及对症治疗。观察组患者除上述常规治疗外, 加用布地奈德雾化吸入, 每日两次, 每次2 mg, 连续用10 d, 并对两组患者治疗后的临床效果进行比较。结果 治疗后第10天, 观察组患者疗效优于对照组, 差异有统计学意义(P < 0.05);观察组总有效率为96.7%, 高于对照组的73.3%。两组患者治疗后的肺功能较治疗前均有所改善, 且观察组FEV1、FEV1/FVC均高于对照组, 差异有统计学意义(P < 0.05)。结论 布地奈德雾化吸入治疗尘肺病合并感染的临床效果较好, 值得在临床上进一步推广和应用。Abstract:Objective To observe the clinical effect of budesonide aerosol in the treatment of infection of pneumoconiosis patients.Methods Totally 60 hospitalized pneumoconiosis patients with infection from January 2014 to January 2015 were studied. They were randomly divided into 2 groups, namely the routine treatment group (n=30) and the specific treatment group (n=30). Patients in the specific treatment group received inhalation of 2 mg budesonide aerosol twice a day for ten days, while the other treatment was the same as that in the control group, such as anti-inflammation, relieving asthma and oxygen therapy. The clinical therapeutic effects of these two groups of patients after treatment were compared.Results On the 10th day after treatment, the curative effect of the specific treatment group was better than that of the routine treatment group (P < 0.05). The total effective rate was 96.7% in the specific treatment group and 73.3% in the routine treatment group. The patients'lung function in both groups was improved, but the FEV1 and FEV1/FVC of patients in the specific treatment group showed much better(P < 0.05).Conclusion The clinical effect of budesonide aerosol in the treatment of complicated infection of pneumoconiosis patients was positive.
下载: